Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The relationships between glutamatergic neurometabolites and cortical thickness in patients with treatment-resistant schizophrenia

FY 2017-18

Summary
Schizophrenia is a severe mental disorder that affects 1% of the global population. A third of patients with schizophrenia fail to respond to conventional antipsychotic medications, and are thus characterized as having treatment-resistant schizophrenia (TRS). Importantly, extensive brain structure abnormalities, including thinning of the outermost layer of the brain (i.e. cortical thinning) may be linked to serious consequences, including increased symptom severity and poor functional outcomes. However, the underlying mechanisms contributing to the structural compromise observed in patients with TRS remain elusive, which necessitates the need for an improved understanding of the abnormal brain processes in TRS. Brain imaging studies implicate glutamate, a chemical that activates brain areas, in TRS. Notably, elevated glutamate levels have been previously observed in this patient population. Cell death linked to abnormally high levels of glutamate may explain structural losses, a phenomenon that remains unexplored in TRS. To better understand structural compromise in TRS, we aim to explore the relationships between glutamate levels and structural measures using brain scans from 30 participants in each of the three groups: (1) TRS patients; (2) patients with schizophrenia responding to conventional antipsychotics; and (3) healthy controls. Our results could guide future diagnostic and treatment strategies for patients with TRS, ultimately improving treatment outcomes and quality of life of this patient population.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
386586
Name
Shah Parita
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The relationships between glutamatergic neurometabolites and cortical thickness in patients with treatment-resistant schizophrenia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Volume; Clozapine; Cortical Thickness; Glutamate; Glutamatergic Neurometabolites; Magnetic Resonance Spectroscopy; Neuroimaging; Neurotoxicity; Schizophrenia; Treatment-Resistant
Abstract
Schizophrenia is a severe mental disorder that affects 1% of the global population. A third of patients with schizophrenia fail to respond to conventional antipsychotic medications, and are thus characterized as having treatment-resistant schizophrenia (TRS). Importantly, extensive brain structure abnormalities, including thinning of the outermost layer of the brain (i.e. cortical thinning) may be linked to serious consequences, including increased symptom severity and poor functional outcomes. However, the underlying mechanisms contributing to the structural compromise observed in patients with TRS remain elusive, which necessitates the need for an improved understanding of the abnormal brain processes in TRS. Brain imaging studies implicate glutamate, a chemical that activates brain areas, in TRS. Notably, elevated glutamate levels have been previously observed in this patient population. Cell death linked to abnormally high levels of glutamate may explain structural losses, a phenomenon that remains unexplored in TRS. To better understand structural compromise in TRS, we aim to explore the relationships between glutamate levels and structural measures using brain scans from 30 participants in each of the three groups: (1) TRS patients; (2) patients with schizophrenia responding to conventional antipsychotics; and (3) healthy controls. Our results could guide future diagnostic and treatment strategies for patients with TRS, ultimately improving treatment outcomes and quality of life of this patient population.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shah, Parita
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~